What Is CJC-1295 Studied For? Research Areas, Per the Published Literature

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH). Its long acting form was engineered to bind albumin in circulation so that stimulation of the pituitary persists for days rather than minutes, a pharmacology described in a human study of healthy adults published in the Journal of Clinical Endocrinology and Metabolism (PMID 16352683). The question "what is CJC-1295 used for" has no approved medical answer, so this page answers a narrower and more honest question: what has CJC-1295 actually been studied for, and what did those studies measure?

CJC-1295 is not approved by the FDA as a medicine for any condition. This page is not guidance.

This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about any health condition or therapy. Nothing below describes how any compound is administered, and no dose, schedule or route is recommended anywhere on this page.

Evidence Map: Where CJC-1295 Appears in the Literature

Research Area 1: Endocrine Pharmacology in Healthy Adults

The single most informative human investigation of CJC-1295 in this citation set is the 2006 study in healthy adults, which was designed to characterise the duration of growth hormone and insulin-like growth factor I (IGF-I) stimulation rather than to treat any disease (PMID 16352683).

What the study measured

In the single dose portion of that work, researchers administered CJC-1295 at 30, 60, 125 and 250 micrograms per kilogram to healthy adults and reported mean growth hormone concentrations that increased approximately 2 to 10 fold for six days or more after a single dose (PMID 16352683). The same study reported mean IGF-I concentrations rising roughly 1.5 to 3 fold and remaining above baseline for 9 to 11 days following a single administration (PMID 16352683). The estimated half life was reported as 5.8 to 8.1 days in that healthy adult population (PMID 16352683).

In the repeated dose portion, researchers used 60 and 90 micrograms per kilogram on repeated schedules and reported that mean IGF-I levels stayed above baseline for up to 28 days (PMID 16352683). The study also reported that growth hormone secretion remained pulsatile rather than becoming a flat elevation, which was one of the stated reasons for interest in GHRH analogs as a class (PMID 16352683).

What the study did not measure

That trial was an endocrine pharmacology and tolerability investigation in healthy volunteers. It did not evaluate injury recovery, body composition endpoints, athletic output, cognition, sleep architecture or longevity, and it was not a treatment trial in any patient population (PMID 16352683). A rise in a hormone marker is a biochemical observation, not a demonstrated clinical outcome, and the published report should be read on those terms.

Research Area 2: Orthopaedics, Sports Medicine and Musculoskeletal Injury

Peptide compounds including GHRH analogs are discussed in recent clinical review literature aimed at orthopaedic and sports medicine audiences. A 2026 review in JAAOS Global Research and Reviews surveyed therapeutic peptides in orthopaedics, covering applications, challenges and future directions (PMID 41490200). A companion style primer in the American Journal of Sports Medicine addressed injectable peptide therapy for orthopaedic and sports medicine physicians, framing the field for clinicians encountering questions about these compounds (PMID 41476424). A 2026 review in Sports Medicine examined the safety and efficacy evidence for both approved and unapproved peptide therapies in musculoskeletal injuries and athletic performance (PMID 41966639).

Plain statement on evidence strength: these are reviews and primers, not controlled trials of CJC-1295. The verified literature on this page contains no randomised controlled human trial testing CJC-1295 for tendon healing, muscle injury, cartilage repair, post-surgical recovery or sports performance. The reviews that discuss the peptide category for musculoskeletal contexts are narrative in structure (PMID 41966639, PMID 41490200), so any expectation of injury benefit from CJC-1295 rests on mechanism reasoning rather than on outcome data.

Research Area 3: Aging and Gerontology

Growth hormone axis decline with age is a long standing topic in gerontology, and GHRH analogs are discussed within it. A 2026 review in Frontiers in Aging addressed therapeutic peptides in gerontology, describing mechanisms and potential applications for healthy aging (PMID 42021992).

Again, the study type matters. A gerontology review summarising mechanisms is not evidence that a specific compound extends healthspan, improves function in older adults or alters disease risk. No trial in this citation set tested CJC-1295 against aging related clinical endpoints such as frailty, bone density, cognition or mortality, and the aging literature cited here is review level (PMID 42021992).

Research Area 4: Aesthetic, Metabolic and Endocrine Contexts

A 2026 review in the International Journal of Molecular Sciences covered therapeutic peptides in aesthetic, metabolic and endocrine conditions, including effects, safety considerations, clinical applications and future perspectives (PMID 42123471). This is the research area where questions about skin, fat distribution and metabolic markers tend to be filed.

The distinction worth holding onto is between a review that places a compound class inside a clinical conversation and a trial that tests a compound against a measured endpoint. For CJC-1295 specifically, the human endpoint data available in this citation set remain the growth hormone and IGF-I measurements from the healthy adult study (PMID 16352683), not aesthetic or metabolic outcomes reported in controlled trials.

Research Area 5: Anti-Doping Detection Science

A substantial share of the peer reviewed work naming CJC-1295 is analytical chemistry developed so that laboratories can detect GHRH analogs in biological samples. A 2021 paper in Drug Testing and Analysis reviewed advances in the detection of growth hormone releasing hormone synthetic analogs (PMID 34665524). Methodological work published in Analytical Science Advances addressed probing for peptidic drugs in the 2 to 10 kilodalton range in doping control blood samples (PMID 38716080), and a 2024 paper in the Journal of Mass Spectrometry described chromatographic mass spectrometric analysis of peptidic analytes of 2 to 10 kilodaltons in doping control urine samples (PMID 38197510).

Detection work also extends to animal sport. A 2019 study in Drug Testing and Analysis described an immuno polymerase chain reaction screen for detecting CJC-1295 and other growth hormone releasing hormone analogs in equine plasma (PMID 30489688). Separately, a 2022 analytical study in Talanta used affinity interaction with the growth hormone secretagogue receptor for early detection of cannabinoids in biological samples (PMID 34736642), which concerns a different receptor from the GHRH receptor that CJC-1295 targets and is included here only to keep the two pathways separate.

The practical reading of this cluster is that regulators and testing laboratories treat CJC-1295 as a substance to be identified, and that much of the published scientific attention it receives is detection oriented rather than therapeutic (PMID 34665524, PMID 38197510).

Research Area 6: Study of Non-Medical Use

One social science investigation appears in this citation set. A 2016 qualitative netnographic study in Substance Use and Misuse analysed publicly available online discourse concerning non-medical use of the synthetic growth hormone secretagogue CJC-1295 among women (PMID 26771670). It was an observational study of how a compound circulates outside medical supervision, not a safety or efficacy study, and its design cannot establish whether any described outcome occurred.

Adverse Events and Safety Signals: What Studies Report

The healthy adult study reported no serious adverse reactions across the doses it administered, with injection site reactions and transient effects described within that report (PMID 16352683). That observation came from a short term investigation in healthy volunteers and does not establish long term safety, safety in people with medical conditions, or safety outside a monitored research setting.

Review literature has raised safety questions about unapproved peptide products as a category. The 2026 Sports Medicine review addressed safety alongside efficacy for approved and unapproved peptide therapies in musculoskeletal and athletic performance contexts (PMID 41966639), and the 2026 review in the International Journal of Molecular Sciences discussed safety within aesthetic, metabolic and endocrine applications (PMID 42123471). Clinical primers for orthopaedic and sports medicine physicians have similarly framed challenges associated with injectable peptide products (PMID 41476424).

Where the Evidence Is Weak or Absent

• Fat loss and body composition: no controlled human trial in this citation set measured fat mass or lean mass changes with CJC-1295; the human data are hormone concentration and half life measurements (PMID 16352683).
• Sleep quality: no study in this citation set tested sleep endpoints with CJC-1295.
• Tendon, ligament or muscle repair: discussed at review level only (PMID 41490200, PMID 41966639), with no CJC-1295 specific outcome trial.
• Anti-aging claims: supported in this set only by a gerontology review of peptide mechanisms (PMID 42021992), not by clinical endpoint data.
• Long term safety: not characterised; the available human safety reporting came from a short term healthy adult study (PMID 16352683).

Regulatory Status and Closing

CJC-1295 is not an approved drug product, and the scientific literature that names it is dominated by one healthy volunteer pharmacology study (PMID 16352683), several recent narrative reviews (PMID 41490200, PMID 42123471), and anti-doping detection methodology (PMID 34665524). CJC-1295 is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about any health condition or therapy.

References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research and Reviews, 2026)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (Frontiers in Aging, 2026)
• Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives (International Journal of Molecular Sciences, 2026)
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions (Substance Use and Misuse, 2016)
• Advances in the detection of growth hormone releasing hormone synthetic analogs (Drug Testing and Analysis, 2021)
• Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor (Talanta, 2022)
• Probing for peptidic drugs (2-10 kDa) in doping control blood samples (Analytical Science Advances, 2022)
• Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples (Journal of Mass Spectrometry, 2024)
• An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma (Drug Testing and Analysis, 2019)